Cassava Sciences Stock Rises 1.8%

Shares of the biotech company saw a modest gain amid analyst commentary.

Apr. 3, 2026 at 4:34am

Got story updates? Submit your updates here. ›

An extreme close-up photograph of intricate financial machinery and equipment, representing the complex inner workings of the stock market and pharmaceutical industry.Cassava Sciences' stock price fluctuates as analysts weigh in on the biotech company's Alzheimer's drug pipeline.Austin Today

Shares of Cassava Sciences (NASDAQ:SAVA) traded up 1.8% on Thursday, closing at $1.72 per share. The stock reached as high as $1.77 during the session, though trading volume declined 63% from the average. Analysts have provided mixed ratings on the stock, with one firm upgrading it to 'hold' while another maintained a 'sell' recommendation.

Why it matters

Cassava Sciences is a clinical-stage biotech company focused on developing treatments for Alzheimer's disease and other neurodegenerative disorders. The stock's performance and analyst coverage provide insight into investor sentiment around the company's drug pipeline and future prospects.

The details

Cassava Sciences' lead drug candidate is simufilam, a small molecule aimed at restoring normal function to a protein implicated in Alzheimer's. The company reported Q4 2025 results in March, with a net loss of $0.26 per share. Analysts expect a full-year 2026 loss of $3.97 per share.

  • Cassava Sciences stock closed at $1.69 on the previous trading day.
  • The stock reached an intraday high of $1.77 on Thursday, April 3, 2026.

The players

Cassava Sciences, Inc.

A clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease and other neurodegenerative disorders.

Wall Street Zen

A research firm that upgraded Cassava Sciences from a 'sell' rating to a 'hold' rating.

Weiss Ratings

A research firm that maintained a 'sell (e+)' rating on Cassava Sciences.

Got photos? Submit your photos here. ›

The takeaway

Cassava Sciences' modest stock gain reflects the mixed analyst sentiment around the company's Alzheimer's drug pipeline and future prospects. Investors will continue to watch for updates on the development of simufilam and the company's financial performance.